Integrin

Cytoskeletal Signaling

HSP Kinesin Microtubule Associated Integrin PAK Glycoprotein MLCK TACC3 Gap-Junction Actin Cardiac Myosin Myosin Arp2/3 Complex KSP Piezo Channel Tight Junction Protein

Isoform-selective Products

ILK

All (24)
Integrin Inhibitors (14)
Integrin Antagonists (8)
Integrin Agonists (2)
New Integrin Products

Cat.No.	Product Name	Information	Product Use Citations
S7077	Cilengitide trifluoroacetate	Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.	J Neuroinflammation, 2025, 22(1):168 Int J Mol Sci, 2025, 26(6)2465 Microbiol Spectr, 2025, 13(2):e0222124
S6387	Cilengitide	Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-707544) is a potent and selective inhibitor of the integrins α_νβ₃ and α_νβ₅ with IC50 of 4 and 79 nM, respectively.	Nat Commun, 2025, 16(1):2254 NPJ Regen Med, 2024, 9(1):4 World J Gastroenterol, 2024, 30(7):728-741
S7540	SB273005	SB273005 is a potent integrin inhibitor with K_i of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.	EMBO J, 2025, 10.1038/s44318-025-00565-3 bioRxiv, 2025, 2025.04.25.650475 Cancer Lett, 2024, 582:216597
S8008	RGD (Arg-Gly-Asp) Peptides	RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.	Adv Sci (Weinh), 2025, 12(18):e2417447 J Sport Health Sci, 2024, S2095-2546(24)00124-8 iScience, 2024, 27(3):109119
S8454	ATN-161	ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.	Nat Commun, 2025, 16(1):6531 Nat Commun, 2025, 16(1):9183 Regen Biomater, 2025, 12:rbaf099
S7844	Cyclo(RGDyK) TFA	Cyclo(RGDyK) TFA is a salt formed by the combination of Cyclo(RGDyK) and trifluoroacetate (TFA). It is an effective and selective Integrin αvβ3 inhibitor with a low IC50 value (e.g., 20 nM). This compound is of great significance in the treatment of cardiovascular diseases, osteoporosis, inflammation and tumors.	J Clin Invest, 2024, e175147 JBMR Plus, 2024, 8(7):ziae066 Cell Commun Signal, 2023, 10.1186/s12964-022-01027-7
S7834	Cyclo(-RGDfK) TFA	Cyclo(-RGDfK) TFA is the salt product of Cyclo(-RGDfK) and trifluoroacetic acid (TFA). The addition of TFA enhances stability and biocompatibility. This compound effectively targets tumor microvessels and cancer cells by specifically binding to the cell surface Integrin αvβ3.	Pharmaceuticals (Basel), 2025, 18(4)549 In Vitro Cell Dev Biol Anim, 2025, 10.1007/s11626-025-01101-7 Sci Adv, 2024, 10(43):eadp4726
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1 (an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S2885	A-205804	A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.	Cell Biol Toxicol, 2024, 40(1):90 Stem Cell Res Ther, 2022, 13(1):218 Am J Rhinol Allergy, 2022, 19458924221086061
S3714	Lifitegrast	Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.	Med Oncol, 2024, 41(8):188 World J Gastroenterol, 2023, 29(20):3103-3118 World J Gastroenterol, 2023, 29(20):3103-3118
S3085	Tirofiban	Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.	Food Funct, 2020, 11(1):139-152
S8594	Tirofiban Hydrochloride	Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 39:101813 Front Cell Infect Microbiol, 2021, 11:783085
S6840	OSU-T315	OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. This compound induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. It exhibits anti-tumor activity.	Exp Eye Res, 2023, 234:109609
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Nat Commun, 2025, 16(1):5461 Signal Transduct Target Ther, 2024, 9(1):109 Signal Transduct Target Ther, 2024, 9(1):109
E1558	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314	TR-14035	TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E4615	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. This compound also inhibits migrasome biogenesis without cytotoxicity. It exhibits potent antitumor activity.	Sci Rep, 2025, 15(1):9147
S4513	RGD peptide (GRGDNP)	RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. This compound induces apoptosis presumably through direct activation of caspase-3.	Tradit Med Res, 2023, 8(9):50
E0790	ILK-IN-3	ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.
E7334	Cyclo(RGDyK)	Cyclo(RGDyK) is a potent and selective inhibitor of αVβ3 integrin . It significantly reduces lung inflammation and fibrosis induced by influenza A virus, and improves lung morphology, lowers pulmonary fibrosis scores, and suppresses the expression of αVβ3, TGF-β1, NF-κB p65, p38 MAPK, and HIF-1α, confirming its protective effects against ALI and pulmonary fibrosis.
E6559^New	GS-1427	GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease.
E7759	GRGDSP	GRGDSP is a fibronectin-derived peptide and an inhibitor of Integrin. It can be used for surface modification of cardiovascular implants, such as vascular grafts, to promote endothelialization, and also holds potential for hepatocellular carcinoma (HCC) treatment by inhibiting tumor cell adhesion and limiting metastasis.
E1385	Bexotegrast (PLN-74809)	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
S3408	A286982	A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.
S7077	Cilengitide trifluoroacetate	Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.	J Neuroinflammation, 2025, 22(1):168 Int J Mol Sci, 2025, 26(6)2465 Microbiol Spectr, 2025, 13(2):e0222124
S6387	Cilengitide	Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-707544) is a potent and selective inhibitor of the integrins α_νβ₃ and α_νβ₅ with IC50 of 4 and 79 nM, respectively.	Nat Commun, 2025, 16(1):2254 NPJ Regen Med, 2024, 9(1):4 World J Gastroenterol, 2024, 30(7):728-741
S7540	SB273005	SB273005 is a potent integrin inhibitor with K_i of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.	EMBO J, 2025, 10.1038/s44318-025-00565-3 bioRxiv, 2025, 2025.04.25.650475 Cancer Lett, 2024, 582:216597
S8008	RGD (Arg-Gly-Asp) Peptides	RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.	Adv Sci (Weinh), 2025, 12(18):e2417447 J Sport Health Sci, 2024, S2095-2546(24)00124-8 iScience, 2024, 27(3):109119
S7844	Cyclo(RGDyK) TFA	Cyclo(RGDyK) TFA is a salt formed by the combination of Cyclo(RGDyK) and trifluoroacetate (TFA). It is an effective and selective Integrin αvβ3 inhibitor with a low IC50 value (e.g., 20 nM). This compound is of great significance in the treatment of cardiovascular diseases, osteoporosis, inflammation and tumors.	J Clin Invest, 2024, e175147 JBMR Plus, 2024, 8(7):ziae066 Cell Commun Signal, 2023, 10.1186/s12964-022-01027-7
S7834	Cyclo(-RGDfK) TFA	Cyclo(-RGDfK) TFA is the salt product of Cyclo(-RGDfK) and trifluoroacetic acid (TFA). The addition of TFA enhances stability and biocompatibility. This compound effectively targets tumor microvessels and cancer cells by specifically binding to the cell surface Integrin αvβ3.	Pharmaceuticals (Basel), 2025, 18(4)549 In Vitro Cell Dev Biol Anim, 2025, 10.1007/s11626-025-01101-7 Sci Adv, 2024, 10(43):eadp4726
S2885	A-205804	A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.	Cell Biol Toxicol, 2024, 40(1):90 Stem Cell Res Ther, 2022, 13(1):218 Am J Rhinol Allergy, 2022, 19458924221086061
S6840	OSU-T315	OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. This compound induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. It exhibits anti-tumor activity.	Exp Eye Res, 2023, 234:109609
S4513	RGD peptide (GRGDNP)	RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. This compound induces apoptosis presumably through direct activation of caspase-3.	Tradit Med Res, 2023, 8(9):50
E0790	ILK-IN-3	ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.
E7334	Cyclo(RGDyK)	Cyclo(RGDyK) is a potent and selective inhibitor of αVβ3 integrin . It significantly reduces lung inflammation and fibrosis induced by influenza A virus, and improves lung morphology, lowers pulmonary fibrosis scores, and suppresses the expression of αVβ3, TGF-β1, NF-κB p65, p38 MAPK, and HIF-1α, confirming its protective effects against ALI and pulmonary fibrosis.
E7759	GRGDSP	GRGDSP is a fibronectin-derived peptide and an inhibitor of Integrin. It can be used for surface modification of cardiovascular implants, such as vascular grafts, to promote endothelialization, and also holds potential for hepatocellular carcinoma (HCC) treatment by inhibiting tumor cell adhesion and limiting metastasis.
E1385	Bexotegrast (PLN-74809)	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
S3408	A286982	A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.
S8454	ATN-161	ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.	Nat Commun, 2025, 16(1):6531 Nat Commun, 2025, 16(1):9183 Regen Biomater, 2025, 12:rbaf099
S3714	Lifitegrast	Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.	Med Oncol, 2024, 41(8):188 World J Gastroenterol, 2023, 29(20):3103-3118 World J Gastroenterol, 2023, 29(20):3103-3118
S3085	Tirofiban	Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.	Food Funct, 2020, 11(1):139-152
S8594	Tirofiban Hydrochloride	Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 39:101813 Front Cell Infect Microbiol, 2021, 11:783085
E1558	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314	TR-14035	TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E4615	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. This compound also inhibits migrasome biogenesis without cytotoxicity. It exhibits potent antitumor activity.	Sci Rep, 2025, 15(1):9147
E6559^New	GS-1427	GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1 (an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Nat Commun, 2025, 16(1):5461 Signal Transduct Target Ther, 2024, 9(1):109 Signal Transduct Target Ther, 2024, 9(1):109
E6559^New	GS-1427	GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease.

Integrin

Cytoskeletal Signaling

Isoform-selective Products

Signaling Pathway Map